Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 28;12:750753. doi: 10.3389/fimmu.2021.750753

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wu, Gao, Kang, Wang, Niu, Liu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Targeting B cells for current and potential therapeutic approaches in RA. (A) Therapeutic approaches already approved in human. (B) Therapeutic approaches under evaluation in human. (C) Potential therapeutic approaches (only tested in mouse model of CIA or in experiments in vitro). Figure 5 summarizes the drugs or cells that target B cells to treat RA. These drugs or cells are either approved in the clinical trial phase of RA, or we believe that they may be used for RA treatment. Jaks, Janus kinases; IL-21R, IL-21 receptor; IL-6R, IL-6 receptor; BAFFR, B cell activating factor receptor; BCMA, B cell maturation antigen; TACI, transmembrane activator and calcium modulator; BTK, Bruton’s tyrosine kinase; anti-FITC CAR-T cell, antifluorescein isothiocyanate chimeric antigen receptor T cells.